Minerva Surgical - UTRS Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Surgical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UTRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UTRS, but not buy additional shares or sell existing shares.
View UTRS analyst ratings or view top-rated stocks.

2 brokers have issued 1 year price objectives for Minerva Surgical's shares. Their UTRS share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,211.0% from the stock's current price.
View analysts price targets for UTRS or view top-rated stocks among Wall Street analysts.

Minerva Surgical's stock was trading at $0.2234 at the beginning of the year. Since then, UTRS shares have increased by 70.7% and is now trading at $0.3814.
View the best growth stocks for 2023 here.

Minerva Surgical saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 448,500 shares, a decline of 51.2% from the December 31st total of 918,400 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are short sold.
View Minerva Surgical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our UTRS earnings forecast.

Minerva Surgical, Inc. (NASDAQ:UTRS) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.12. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $12.64 million. Minerva Surgical had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 51.99%.

Minerva Surgical updated its FY 2022 earnings guidance on Wednesday, December, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50.00 million-$53.00 million, compared to the consensus revenue estimate of $50.85 million.

(UTRS) raised $100 million in an IPO on Friday, October 22nd 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

Minerva Surgical trades on the NASDAQ under the ticker symbol "UTRS."

Shares of UTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTRS stock can currently be purchased for approximately $0.38.

Minerva Surgical (NASDAQ:UTRS) has a market capitalization of $11.37 million and generates $52.10 million in revenue each year.

The company employs 157 workers across the globe.

The official website for the company is www.minervasurgical.com. The company can be reached via phone at 855-646-7874 or via email at caroline.corner@westwicke.com.